Sanofi Cholesterol Drug Beats Merck’s Zetia in Study
This article is for subscribers only.
Sanofi and Regeneron Pharmaceuticals Inc.’s experimental treatment alirocumab lowered cholesterol three times more than Merck & Co.’s Zetia in the first late-stage study of a drug that may garner $3 billion sales annually.
In a trial dubbed Odyssey Mono that involved 103 patients, alirocumab reduced levels of LDL, so-called bad cholesterol, by 47 percent after 24 weeks of treatment, compared with 16 percent among those receiving Zetia, the companies said in an e-mailed statement today.